CD274 and cancer: PD-1/PD-L1 blockade has emerged as a major immunotherapeutic strategy across multiple cancers, yet its efficacy is often limited by intrinsic and acquired resistance mechanisms related to antigen presentation defects and immunosuppressive microenvironments (22).